Alphalisa pnfh (hu) kit 100pts 100 Tests

Alternative ELISA et WB, plus simple, plus rapide, très sensible, excellente gamme dynamique (5log), facilement miniaturisable / automatisable et peu onéreuse.

Formats: Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample). Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). AlphaLISA features: No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm. Phosphorylated neurofilament heavy chain protein (pNFH) is also known as NF-200; NF200; NEFH; N52; Neurofilament heavy polypeptide; Neurofilament triplet H protein; 200 kDa neurofilament protein; KIAA0845. It is a 200 kDa subunit of the three so-called neurofilament triplet proteins: light (68 kDa), medium (160 kDa) and heavy (200 kDa), which are major structural components of neurons. High levels of neurofilament have been observed during the progression of numerous neurological diseases. Many studies have demonstrated that pNFH can be used as a biomarker to monitor neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and ischemic stroke.